A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance

• Главные авторы: Lei Sun (Автор), Arabella H. Wan (Автор), Shijia Yan (Автор), Ruonian Liu (Автор), Jiarui Li (Автор), Zhuolong Zhou (Автор), Ruirui Wu (Автор), Dongshi Chen (Автор), Xianzhang Bu (Автор), Jingxing Ou (Автор), Kai Li (Автор), Xiongbin Lu (Автор), Guohui Wan (Автор), Zunfu Ke (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2024-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Lenvatinib, a second-generation multi-receptor tyrosine kinase inhibitor approved by the FDA for first-line treatment of advanced liver cancer, facing limitations due to drug resistance. Here, we applied a multidimensional, high-throughput screening platform comprising patient-derived resistant live...